Regulation - GlaxoSmithKline, Tropical diseases

Filter

Popular Filters

FDA “Breakthrough Therapy” designation for GSK’s malaria drug tafenoquine; EU Cervarix news

FDA “Breakthrough Therapy” designation for GSK’s malaria drug tafenoquine; EU Cervarix news

22-12-2013

The US Food and Drug Administration has granted “Breakthrough Therapy” designation for tafenoquine,…

CervarixEuropeGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationtafenoquineTropical diseases

New data support GSK plan to file for approval of malaria vaccine in 2014

New data support GSK plan to file for approval of malaria vaccine in 2014

08-10-2013

Results from a large-scale Phase III trial, presented today at the Multilateral Initiative on Malaria…

GlaxoSmithKlinePharmaceuticalRegulationResearchRTS,STropical diseasesVaccines

Regulatory briefs from GSK/Theravance, Allergan and Mylan

19-12-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX0 have submitted a…

AllerganAnoro ElliptaBotoxEuropeGenericsGenito-urinaryGlaxoSmithKlineMylan LaboratoriesNorth AmericaPharmaceuticalQualaquinRegulationRelvarRespiratory and PulmonaryTheravanceTropical diseases

Back to top